PMID- 19133674
OWN - NLM
STAT- MEDLINE
DCOM- 20090528
LR  - 20191210
IS  - 1522-726X (Electronic)
IS  - 1522-1946 (Linking)
VI  - 73
IP  - 5
DP  - 2009 Apr 1
TI  - Transcatheter closure of atrial septal defect in elderly patients with permanent 
      atrial fibrillation.
PG  - 682-6
LID - 10.1002/ccd.21870 [doi]
AB  - OBJECTIVES: The aim of this study is to evaluate the feasibility and efficacy of 
      device closure of atrial septal defect (ASD) in elderly patients with permanent 
      atrial fibrillation. BACKGROUND: Little is known about the feasibility of device 
      closure of ASD in those patients. METHODS: Nine consecutive patients (mean age 
      68.1 years) with permanent atrial fibrillation (>1 year persistent) underwent 
      catheter closure using the Amplatzer septal occluder. Transthoracic 
      echocardiography and plasma B-type natriuretic peptide (BNP) level were assessed 
      before and at 24 hours; and 1, 3, and >6 months after the closure. Before the 
      procedure, appropriate dose of warfarin was used in all, diuretics was used in 
      8/9. Same amount of medications were continued after the procedure. RESULTS: ASD 
      could be closed in all (mean device size 27.3 mm) without hemodynamic and 
      thromboembolic complications. New York Heart Association (NYHA) functional 
      classification was significantly improved in all patients after device closure. 
      No hemodynamic and thromboembolic complications were observed during the 
      follow-up period (mean 10.6 months). Although permanent atrial fibrillation did 
      not change in all after the procedure, resting heart rate decreased from 76.2 +/- 
      16.0 to 68.3 +/- 13.2 beats/min (P = 0.015). There was statistically significant 
      improvement in right ventricular/left ventricular diameter ratio (1.08 +/- 0.16 
      to 0.73 +/- 0.10, P = 0.008) and plasma BNP level (183.7 +/- 90.5 to 94.6 +/- 
      47.4 pg/mL, P = 0.008) after >6 months device closure. CONCLUSIONS: Even in the 
      patients complicated with permanent fibrillation, transcatheter closure of ASD 
      can contribute to symptomatic improvement as well as cardiac geometric 
      remodeling.
CI  - Copyright 2009 Wiley-Liss, Inc.
FAU - Taniguchi, Manabu
AU  - Taniguchi M
AD  - Division of Cardiac Care Unit, Okayama University Hospital, Okayama, Japan. 
      tmnb@md.okayama-u.ac.jp
FAU - Akagi, Teiji
AU  - Akagi T
FAU - Ohtsuki, Shinichi
AU  - Ohtsuki S
FAU - Okamoto, Yoshio
AU  - Okamoto Y
FAU - Tanabe, Yasuharu
AU  - Tanabe Y
FAU - Watanabe, Nobuhisa
AU  - Watanabe N
FAU - Nakagawa, Koji
AU  - Nakagawa K
FAU - Toh, Norihisa
AU  - Toh N
FAU - Kusano, Kengo
AU  - Kusano K
FAU - Sano, Shunji
AU  - Sano S
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Catheter Cardiovasc Interv
JT  - Catheterization and cardiovascular interventions : official journal of the 
      Society for Cardiac Angiography & Interventions
JID - 100884139
RN  - 0 (Anticoagulants)
RN  - 0 (Biomarkers)
RN  - 0 (Diuretics)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
RN  - 5Q7ZVV76EI (Warfarin)
SB  - IM
CIN - Catheter Cardiovasc Interv. 2009 Apr 1;73(5):687. PMID: 19309705
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/therapeutic use
MH  - Atrial Fibrillation/blood/*etiology/physiopathology/therapy
MH  - Biomarkers/blood
MH  - *Cardiac Catheterization/instrumentation
MH  - Diuretics/therapeutic use
MH  - Echocardiography, Transesophageal
MH  - Equipment Design
MH  - Feasibility Studies
MH  - Female
MH  - Heart Septal Defects, Atrial/blood/complications/physiopathology/*therapy
MH  - Hemodynamics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/blood
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left
MH  - Ventricular Function, Right
MH  - Ventricular Remodeling
MH  - Warfarin/therapeutic use
EDAT- 2009/01/13 09:00
MHDA- 2009/05/29 09:00
CRDT- 2009/01/13 09:00
PHST- 2009/01/13 09:00 [entrez]
PHST- 2009/01/13 09:00 [pubmed]
PHST- 2009/05/29 09:00 [medline]
AID - 10.1002/ccd.21870 [doi]
PST - ppublish
SO  - Catheter Cardiovasc Interv. 2009 Apr 1;73(5):682-6. doi: 10.1002/ccd.21870.